• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt’s Mead

by October 30, 2024
written by October 30, 2024

By Brendan Pierson

(Reuters) – A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt’s Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies’ formulas for premature babies caused a severe intestinal illness.

Litigation over the formulas has raised alarm from doctors who say that it could threaten the formulas’ availability or affect medical decisions. CEOs for both Reckitt and Abbott have said the companies may exit the premature formula market.

“Companies have to clearly and unambiguously tell us the truth about their products, especially those intended for the smallest and most vulnerable human beings on the planet,” Tim Cronin, representing Elizabeth Whitfield and her son Kaine, told the jury in St. Louis, Missouri, in his closing argument at the end of a five-week trial.

Cronin said the companies failed to warn that their premature baby formulas could cause necrotizing enterocolitis, and that Kaine got the disease as a result of receiving the formula in the newborn intensive care unit at St. Louis Children’s Hospital in 2017, leaving him with lifelong health and developmental problems.

Cronin asked the jury to award Kaine nearly $277 million in compensatory damages for his past and future healthcare costs, lost earning potential and pain and suffering. He also urged them to order Abbott to pay $5 billion in punitive damages, and Mead Johnson to pay $1 billion, based on the companies’ sizes.

The verdict Whitfield is seeking would be one of the largest in U.S. history. Even if the jury awards it, however, it could be reduced on appeal for a number of reasons, including that the U.S. Supreme Court has ruled that punitive damages should generally be less than 10 times compensatory damages.

While the hospital was also a defendant in the case, Cronin did not ask the jurors to award any damages against it, though he said they were free to do so.

Reuters watched the closing argument through Courtroom View Network.

Lawyers for the defendants are expected to present their closing arguments later in the day.

Both companies have said that, while mother’s and donated human milk is widely understood to protect against necrotizing enterocolitis, formula does not cause it.

Whitfield’s case is one of close to 1,000 in courts around the United States alleging that Abbott’s and Mead’s specialized formulas used by hospitals to feed premature babies cause the illness. Two cases that previously went to trial resulted in verdicts of $60 million against Mead and $495 million against Abbott.

Following the earlier verdicts, U.S. regulatory agencies and a working group of scientists convened by the National Institutes of Health have said current evidence does not support the hypothesis that formula causes necrotizing enterocolitis. Abbott and Mead were not allowed to present those statements to the jury in the current trial.

Abbott’s lead trial lawyer, Kirkland & Ellis partner James Hurst, will not be allowed to present his closing argument for the company after Missouri Circuit Court Judge Michael Noble last week found he had acted in “bad faith” during the trial, including by trying to bring in testimony that the judge had already ruled was not allowed.

An Abbott spokesperson in a statement said that Hurst “is a terrific trial lawyer and has acted professionally, ethically and in good faith throughout the case.”

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Explainer-Who in the US benefits from $35 insulin?
next post
Facebook parent Meta projects sharp acceleration in AI costs after results beat Wall Street targets

You may also like

BASF results down on impairments, restructuring

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Sign up and get the scoop before anyone else—fresh updates, and secret deals, all wrapped up just for you. We're talking juicy tips, fun surprises, and invites to events you actually want to go to. Don’t just watch from the sidelines—jump in and be part of the magic!








    By signing up, you're cool with getting emails from us. Don’t worry — your info stays safe, sound, and strictly confidential. No spam, no funny business. Just the good stuff.

    Recent Posts

    • Elon Musk’s SpaceX acquires xAI

      February 25, 2026
    • The architect of Amazon’s supply chain on running a startup with your spouse

      February 25, 2026
    • Trump administration alleges Nike discriminated against white workers

      February 25, 2026
    • Landmark trial accusing social media companies of addicting children to their platforms begins

      February 25, 2026

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (688)
    • Stock (6,426)

    Latest News

    • Elon Musk’s SpaceX acquires xAI
    • The architect of Amazon’s supply chain on running a startup with your spouse

    Popular News

    • WHO chief calls for end to hospital attacks in Gaza after strike
    • Volkswagen shares fall as markets struggles to digest unions deal

    About The Significant deals

    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2026 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy